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Annals of Surgery  Volume 270, Number 2, August 2019Background: Although studies have shown that perioperative IMN may
reduce postoperative infectious complications, many of these have included
patients with benign and malignant disease, and the optimal timing of such an
intervention is not clear.
Methods: The Embase, Medline, and Cochrane databases were searched
from 2000 to 2018, for prospective randomized controlled trials evaluating
preoperative oral or enteral IMN in patients undergoing surgery for gastroin-
testinal cancer. The primary endpoint was the development of postoperative
infectious complications. Secondary endpoints included postoperative non-
infectious complications, length of stay, and up to 30-day mortality. The
analysis was performed using RevMan v5.3 software.
Results: Sixteen studies reporting on 1387 patients (715 IMN group, 672
control group) were included. Six of the included studies reported on a mixed
population of patients undergoing all gastrointestinal cancer surgery. Of the
remaining, 4 investigated IMN in colorectal cancer surgery, 2 in pancreatic
surgery, and another 2 in patients undergoing surgery for gastric cancer. There
was 1 study each on liver and esophageal cancer. The formulation of nutrition
used in all studies in the treated patients was Impact (Novartis/Nestle´), which
contains v-3 fatty acids, arginine, and nucleotides. Preoperative IMN in
patients undergoing surgery for gastrointestinal cancer reduced infectious
complications [odds ratio (OR) 0.52, 95% confidence interval (CI) 0.38–0.71,
P < 0.0001, I2 ¼ 16%, n ¼ 1387] and length of hospital stay (weighted mean
difference 1.57 days, 95% CI 2.48 to 0.66, P ¼ 0.0007, I2 ¼ 34%, n ¼
995) when compared with control (isocaloric isonitrogeneous feed or normal
diet). It, however, did not affect noninfectious complications (OR 0.98, 95%
CI 0.73–1.33, P ¼ 0.91, I2 ¼ 0%, n ¼ 1303) or mortality (OR 0.55, 95% CI
0.18–1.68, P ¼ 0.29, I2 ¼ 0%, n ¼ 955).
Conclusion: Given the significant impact on infectious complications and a
tendency to shorten length of stay, preoperative IMN should be encouraged in
routine practice in patients undergoing surgery for gastrointestinal cancer.
Keywords: cancer surgery, gastrointestinal cancer, immune modulating
nutrition, infectious complications, postoperative outcomes, preoperative
nutrition
(Ann Surg 2019;270:247–256)
Impairment of nutritional status is common in cancers of the gastro-intestinal tract, where the prevalence of malnutrition ranges from
20% to 70%.1–3 The wide variation in prevalence is, in part, due to the
underlying cancer type, stage, and grade, and also the patient-specific
factors such as age and comorbidity.2 Malnutrition impacts negatively
on the host immune response and the process of tissue healing,4,5 and is
an independent risk factor for postoperative complications.6 The high
cellular turnover during the process of tumuorigenesis1,2 also leads to a
dysregulation of the immune response in patients with cancer, com-
pounding their risk of developing complications. Definitive treatment
of cancers of the gastrointestinal tract invariably involves surgical
intervention. However, it is well-documented that the catabolic
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dysregulation of the immune response resulting in an increased risk of
postoperative complications, in particular, infectious complica-
tions.1,7–9 It is, therefore, predictable that patients with gastrointestinal
cancer undergoing surgical resection are at a much greater risk of
posoperative complications.
It is for these patients, that the concept of preoperative
immune modulating nutrition (IMN) or pharmaconutrition, which
involves the use of novel nutrients to improve nutritional status and to
modulate host immune systems and inflammatory response to
stress,10–12 seems a promising treatment.13 There is no universally
accepted definition of IMN, however, it is characterized by the
addition of special nutrients in higher doses than in standard nutri-
tional protocols.2,3 The generally accepted and most frequently
recognized immune-modulating nutrients are various combinations
of arginine, fish oil (v-3 fatty acids), nucleotides, and glutamine.10
Partial immunonutrients include antioxidants (vitamins E and C,
selenium, or beta carotene).10 Several reviews and meta-analy-
ses10,14,15 have demonstrated the beneficial effects of IMN by
pooling results of randomized control trials (RCTs) in all surgical
patients examining the preoperative, perioperative, and postoperative
periods of treatment in tandem. However, others have failed to
demonstrate any added benefit of IMN over standard supplements
using similar methods.16,17 Therefore, there has been a reluctance to
recommend ‘‘immunonutrition’’ for routine use.1–3 Focusing on
conditioning the immune system for surgery, administration in the
preoperative period may be most reasonable. However, there is still a
lack of clarity for the indication, route, timing, and optimal duration
of preoperative treatment.14–16 As the risk of malnutrition and the
inflammatory response profiles in cancer surgery are expected to
differ from surgery for benign disease, pooling of the results of these
patients with benign and malignant disease may yield ambiguous
outcomes. Likewise, the evidence from animal studies suggested that
a minimum of 72 hours were required for maximal effects of
enterally administered IMN to be evident on the composition of
macrophage phospholipid.11 Additionally, in studies that examined
IMN in the postoperative period, up to 5 days were required for the
full dose of enteral IMN to be delivered.13 There is no prior
systematic review evaluating the preoperative IMN in patients
undergoing surgery for gastrointestinal cancer, specifically with
due consideration to route and timing of initiation of treatment.
This systematic review and meta-analysis, therefore, inves-
tigated the impact of oral or enteral IMN administered a minimum
of 3 days and restricted to the preoperative period on postoperative
outcomes in patients undergoing surgery for gastrointestinal
cancer.
METHODS
Search Strategy
A comprehensive and systematic search of the Embase,
Cochrane Collaboration, and Medline databases was undertaken
to identify relevant studies published between 2000 and 2018.
The terms relating to preoperative, preoperative period, preoperative
care, and prehabilitation were combined with terms relating to
immunonutrition, immune-enhancing nutrition, IMN, pharmaconu-
trition, and then to postoperative and postsurgical outcomes.
The following Medical Subject Headings (MeSH) were used:
‘‘Preoperative Period’’, ‘‘Preoperative Care’’, ‘‘Preoperative’’,
‘‘preop’’, ‘‘Nutrition(al) Assessment’’, ‘‘Parenteral Nutrition’’,
‘‘Enteral Nutrition’’, Nutrition Disorders’’, Nutrition Surveys’’,
‘‘Home/ or nutrition’’, ‘‘Total/Nutrition Therapy’’ combined with
‘‘post-operative outcomes’’. (Supplementary document—Supple-
mentary Table 1, http://links.lww.com/SLA/B601). The bibliography
248 | www.annalsofsurgery.comof the studies that met the inclusion criteria were searched for
additional trials or reports relevant to this meta-analysis.
Criteria for Considering Studies for the Review
All studies on patients undergoing surgery for gastrointestinal
cancer were considered. The intervention of interest was IMN
defined specifically to include all types and combinations of argi-
nine, glutamine, v-3 fatty acids, and nucleotides provided as part of
oral supplementation or enteral nutrition, and crucially commenced
a minimum of 3 days before the intended date of surgery. The
primary outcome measure was postoperative infectious complica-
tions. Secondary outcomes of interest included length of hospital
stay (LOS), noninfectious complications, and mortality up to
30 days postoperatively.
Inclusion Criteria
Prospective RCTs reporting at least 1 relevant clinical out-
come were included. The studies had to be in human subjects over
the age of 18 years undergoing surgery for gastrointestinal cancer.
The control arm was either an isocaloric isonitrogeneous nonim-
mune-enhancing feed or normal diet with no supplementation. No
language limitations were applied.
Exclusion Criteria
Studies which failed to fulfil the inclusion criteria such as
nonrandomized or retrospective studies were excluded. This was to
reduce the potential risk of bias in such studies. Studies that only used
singular components of recognized IMN such as ‘‘only v-3 fatty
acids,’’ ‘‘only arginine,’’ and so on were also excluded. Additionally,
studies that failed to report patient data, duplicated studies, those
with restricted access to study report or data, review articles, letters to
the editor, editorial reports, case reports, and conference abstracts
with no access to the entire study or report were also excluded.
Studies that reported perioperative or postoperative administration of
IMN were also excluded, along with studies published before the
inclusion date. Studies that would have otherwise met inclusion
criteria, but reported on both cancer and noncancer gastrointestinal
surgery and did not provide data for the cancer patients separately,
were also excluded if attempts to get source data failed. The
identified studies were screened for relevance to this review inde-
pendently by 2 reviewers (P.S. and A.A.). All discordant articles were
adjudicated by a third reviewer (D.N.L.).
Data Extraction, Collection, and Synthesis
Data were retrieved from the selected study texts using a
predetermined data extraction form. Data were collected on publica-
tion details, study design, number of participants, type of gastrointes-
tinal surgery, participant age, intervention or treatment investigated,
follow-up period, 30-day mortality, readmissions, postoperative nutri-
tional assessments, and LOS. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement18 was adhered
to, all studies were appraised critically, and the risk of bias of all
included studies assessed. A recent multicenter study from Australia
used a 2 2 factorial design randomizing for IMN versus placebo
before and after surgery.19 For our analysis, only the data from the
patient groups with IMN before surgery versus control were included.
Statistical Analysis
For the meta-analysis, dichotomous outcome measures were
summarized as odds ratios (ORs) or weighted mean differences
(WMDs) with 95% confidence intervals (CIs) for continuous variables.
The presence of statistical heterogeneity was to some degree expected,
given the in-between study variability20 in type and grade of cancer
evaluated, the number of patients per study, the percentage of study
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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of controls, and the duration of therapy. Therefore, quantitative syn-
thesis of the pooled data was performed using RevMan v5.3 software21
assuming a random-effects meta-analysis. Heterogeneity was assessed
using the I2 statistic,22 and defined as low, moderate, or high corre-
sponding to upper limits of 25%, 50%, and 75%, respectively.20 The
assessment of publication bias was undertaken by assessing symmetry
of the funnel plot for the primary outcome. Predetermined separate
analyses were performed according to what the ‘‘control’’ group
received (ie, isocaloric isonitrogenous feed or standard diet without
supplements) and the results were pooled together.
Registration of Systematic Review
The protocol for this systematic review and meta-analysis wasregistered with the PROSPERO database (http://www.crd.york.ac.uk/
FIGURE 1. Preferred Reporting Items for Systematic Reviews and
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.PROSPERO/), and the registration number assigned was
CRD42018079236.
RESULTS
Inclusion of Studies
After screening, 64 full papers were evaluated of which 16 met
the inclusion criteria (Fig. 1).19,23–37 The detailed study character-
istics and patient demographics are provided in Tables 1 and 2. Seven
studies originated from Japan,23,27,32–36 3 from Italy,24,25,29 and 1
each from Spain,26 Denmark,28 Switzerland,30 Turkey,31 Australia,19
and China.37 Six of the studies included reported on a mixed
population of patients undergoing all gastrointestinal cancer sur-
gery.25,29–31,35,37 Of the remaining, 4 investigated IMN in colorectal
24,26,32,34 23,28cancer surgery, 2 in pancreatic surgery, and a further 2
Meta-Analyses (PRISMA) flow diagram.
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TABLE 1. Characteristics of Included Studies
Study, Year Country Feeding Protocol Days Product in Treatment Group Dose
Control
(Isocal/IsoN)
Aida et al, 201423 Japan OS day in addition to standard diet 5 Impact (Novartis Pharma, Tokyo) 1000 mL/d No supplement
Braga et al, 200224 Italy OS in addition to standard diet 5 Impact (Novartis, Bern) 1000 mL/d Yes
Braga et al, 200225 Italy OS in addition to standard diet 7 Impact (Novartis, Bern) 1000 mL/d No supplement
Fujitani et al, 201227 Japan OS in addition to standard diet 5 Oral Impact (Novartis Pharma,
Tokyo)
1000 mL/d No supplement
Gade et al, 201628 Denmark OS in addition to standard diet 7 Oral Impact (Nestle, Vevey) 1.5 g protein/kg
body weight
No supplement
Gianotti et al, 200229 Italy OS in addition to standard diet 5 Impact (Novartis, Bern) 1000 mL/d No supplement
Giger-Pabst et al, 201330 Germany OS in addition to standard diet 3 Impact (Novartis, Bern) 750 mL/d Yes
Gunerhan et al, 200931 Turkey Total enteral nutrition 7 Impact (Novartis, Bern) Harris-Benedict Yes
Horie et al, 200632 Japan OS in addition to standard diet 6 Impact (Novartis Pharma, Tokyo) 750 mL/d No supplement
Manzanares Campillo
et al, 201726
Spain OS in addition to standard l diet 8 Oral Impact (Novartis, Espana) 1000 kcal/d No supplement
Mikagi et al, 201133 Japan OS in addition to standard diet 5 Impact (Novartis Ajinomoto
Pharma,
Tokyo)
750 mL/d No supplement
Moriya, 201534 Japan OS in addition to standard diet 5 Impact (Novartis Pharma, Tokyo) Low: 250 mL/dy
High: 750 mL/dy
No supplement
Mudge et al, 201819 Australia OS in addition to standard dietz 7 Oral Impact (Novartis) 909 kcal/d Yes
Nakamura et al, 200535 Japan OS in addition to standard diet 5 Impact (Novartis Pharma, Tokyo) 1000 mL/d No supplement
Okamoto et al, 200936 Japan OS in addition to standard diet 7 Impact (Novartis, Bern) 750 mL/d Yes
Xu et al, 200637 China Enteral nutrition þ standard diet 7 Impact (Novartis, Beijing) 25 kcal/d Yes
If control was an isocaloric and isonitrogenous supplement—yes (normal diet—no supplement).
yThey had a low volume and high volume subgroups receiving 250 mL and 750 mL. Those patient groups are both counted together as treated.
zFor patients with total dysphagia the supplements were dissolved and administered via a nasogastric feeding tube or jejunostomy.
OS indicates oral supplements.
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1 study each on hepatic33 and esophageal cancer.19 The additional
randomized studies evaluated but excluded due to specific data on
cancer patients not being available38,39 or outside study period40 are
presented in the Supplementary Document (Supplementary Table 2,
http://links.lww.com/SLA/B601).38–44
Patient Characteristics
Sixteen studies 1387 patients (715 IMN group, 672 control
group) were included.19,23–37 Five studies specifically reported
patients with and without weight loss.19,23,24,27,31 Three studies
included only well-nourished patients as assessed with Nutritional
risk screening 200245 or determined to have less than 10% weight
loss in a year.29,30,32 A single study reported a full cohort of
malnourished patients undergoing surgery for various types of
gastrointestinal cancer.24 The remaining 7 studies failed to report
whether their cohorts were well-nourished, malnourished, or
mixed.26,28,33–37
Supplemental Nutrition and Administration
In all the studies, the formulation of nutrition was ‘‘Impact’’
(Novartis/Nestle´), which contains v-3 fatty acids, arginine, and
nucleotides (Supplementary document—Supplementary Table 3,
http://links.lww.com/SLA/B601), but the regimen, dosage, and dura-
tion of treatment varied between studies (Table 1). A study from
Japan34 included what they described as high dose (750 mL/d) and
low dose (250 mL/d) of IMN. However, for this intention-to-treat-
based analysis, their patients are classed as treated irrespective of
dosage. The characteristics of the nutrition supplementation are
detailed in Table 1. In 6 studies, the control arm was an isocaloric
isonitrogeneous feed.19,24,30,31,36,37 In the remaining 10 studies,23,25–
29,32–35 no supplementation was provided to the control arm and the
patients were expected to have a standard diet. Most of the studies
evaluated postoperative infectious complications as their primary or
250 | www.annalsofsurgery.comsecondary outcome measure. The others included length of stay,
overall morbidity, and mortality. Some studies also reported variables
related to immune response and inflammation such as postoperative
interleukin-6 and C-reactive protein.
Results of Meta-analysis
The results of the meta-analysis are summarized in Table 3 and
Figs. 2 and 3.
Primary Outcome: Infectious Complications
All 16 studies19,23–37 provided relevant data for infectious
complications. Fig. 2A and Table 3 show the incidence rates of
infectious complications in the treated (IMN) versus untreated
(isocaloric isonitrogenous supplements, or standard diet groups).
The event rate of this outcome was 18.6% (133/715 patients) in
the IMN group compared with 29.31% (199/672 patients) in the
control group. The pooled OR for infectious complications after
preoperative treatment with immune modulating nutrients was 0.52
(95% CI 0.38–0.71, P < 0.0001, I2 ¼ 16%).
The OR for infectious complications was then examined by
the choice of control. In the studies where the control arms received
an isocaloric isonitrogenous supplement,19,24,30,31,36,37, the OR was
0.49 (95% CI 0.28–0.85, P ¼ 0.01, I2 ¼ 0.25%), and for those
receiving no supplements,23,25–29,32–35 OR was 0.52 (95% CI 0.35–
0.78, P ¼ 0.001, I2 ¼ 20%).
Secondary Outcomes
The secondary outcomes of clinical significance consistently
reported in the included studies were LOS, mortality, and noninfec-
tious complications. However, the definition of what constituted
noninfectious morbidity varied. The nutritional and immunology
variables reported by some studies were not investigated consistently,
nor were they reported in a manner that allowed for accurate pooling
of their results.
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
TABLE 2. Nutritional Protocols of Included Studies
Study, Year
No. of
Participants Type of Cancer
Malnutrition
Rates, %
Definition of
Malnutrition Primary Endpoint Secondary End-
point
Source of
Funding
Aida et al, 2014
23
50 Pancreatic cancer 8% Loss of >10%
body weight
Infectious
complications
Immune responses Grant from
Japanese
Society for
Parenteral
and Enteral
Nutrition
Braga et al, 2002
24
100 Colorectal cancer 20% More than 10%
weight loss in
6 months
Delayed
hypersensitivity
response and IL-6
levels
Infectious
complications,
noninfectious
complications,
anastomotic
leak, LOS,
mortality
Novartis
Braga et al, 2002
25
100 All gastrointestinal
cancer
100% More than 10%
weight loss in
6 months
Postoperative
complications
LOS Novartis
Fujitani et al, 2012
27
231 Gastric cancer 2.2% Less than 10%
weight loss in
6 months
Surgical site infection Infection,
morbidity, C-
reactive protein
Not reported
Gade et al, 2016
28
35 Pancreatic cancer Not reported NRS 2002 Postoperative
complications
LOS Education grant
from the
University
of
Copenhagen
Gianotti et al, 2002
29
204 All gastrointestinal
cancer
0 More than 10%
loss in 6
months
Infectious
complications,
length of stay
Gut function,
compliance
Novartis
Giger-Pabst et al, 2013
30
108 All gastrointestinal
cancer
0 NRS 2002 Rate of postoperative
complications
Infectious
complications,
noninfectious
complications,
LOS
Novartis
Gunerhan et al, 2009
31
24 All gastrointestinal
cancer
1% PG-SGA Nutritional parameters,
blood markers
(prealbumin,
albumin,
lymphocyte count)
Infectious
complications,
noninfectious
complications,
LOS
Not reported
Horie et al, 2006
32
67 Colorectal cancer 0 Not reported Surgical site infection Postoperative
inflammation
and nutrition
Not reported
Manzanares Campillo
et al, 2017
26
84 Colorectal cancer Not reported Not reported Infectious
complications
Minor and major
complications,
length of stay
and cost
Not reported
Mikagi et al, 2011
33
26 Liver cancer Not reported Not reported Indices of
inflammatory
reaction
(interleukin-6,
white cell count)
Postoperative
complications,
length of stay
Not reported
Moriya, 2015
34
85 Colorectal cancer Not reported Not reported Surgical site infection Infection,
morbidity, LOS
Not reported
Mudge et al, 2018
19
127 Esophageal cancer 17% PG-SGA Infective complications Noninfective
complications,
LOS, intensive
care unit stay,
mortality
Medical
Research
Council,
Australia,
Project
Grant
Nakamura et al, 2005
35
26 All gastrointestinal
cancer
Not reported Not reported Inflammatory
mediators, and
blood markers and
Changes in EPA,
DHA, LA, AA
LOS, postoperative
complications
Not reported
Okamoto et al, 2009
36
60 Gastric cancer Not reported Not reported Immunological and
nutritional
variables
Postoperative
complications
Not reported
Xu et al, 2006
37
60 All gastrointestinal
cancer
Not reported Not reported Immunological and
nutritional
variables
Postoperative
complications
Not reported
AA indicates arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; NRS 2002, Nutrition Risk Screening 2002; PG-SGA, Scored Patient-
Generated Subjective Global Assessment.
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TABLE 3. Summary of Pooled Results
Outcome or Subgroup No. of Studies Participants Statistical Method Effect Estimate
Infectious complications 16 1387 Odds ratio (M-H, random, 95% CI) 0.52 [0.38, 0.71]
Noninfectious complications 15 1303 Odds ratio (M-H, random, 95% CI) 0.98 [0.73, 1.33]
Length of stay 12 995 Mean difference (IV, random, 95% CI) 1.57 [2.48, 0.66]
Mortality 8 955 Odds ratio (M-H, random, 95% CI) 0.55 [0.18, 1.68]
Adiamah et al Annals of Surgery  Volume 270, Number 2, August 2019Noninfectious Complications. The incidence of noninfec-
tious complications was reported in fifteen studies19,23–25,27–37
(Fig. 2B, Table 3). The event rate of this outcome was 20.21%
(136/673 patients) in the IMN group and 20.79% (131/630 patients)
in the control arm. The pooled OR for noninfectious complications
was 0.98 (95% CI 0.73–1.33, P ¼ 0.91, I2 ¼ 0%).
Length of Stay. Twelve studies provided complete data on
LOS.19,24–26,28–32,35–37 The pooled WMD was 1.57 (95% CI
2.48 to 0.66, P ¼ 0.00007, I2 ¼ 34%; Fig. 3A). However,
subgroup analysis of the group receiving supplements did not reach
significance (OR1.06, 95% CI2.76 to 0.63, P¼ 0.22, I2¼ 63%).
Mortality. Eight studies reported on perioperative mortal-
ity,19,23–25,27–30 and in 2 studies there were no deaths at up to 30
days.24,27 In the remainder mortality was a rare event. Mortality rates
were 1.03% (5/486 patients) in the IMN group and 2.56% (12/469
patients) in the control group. The pooled OR for mortality was 0.55
(95% CI 0.18–1.68, P ¼ 0.29, I2 ¼ 0%; Fig. 3B, Table 3).
Heterogeneity and Publication Bias
Statistical heterogeneity in this meta-analysis was relatively
low, ranging from 0% to 39% (Figs. 2 and 3). The possibility of
publication bias was assessed in the funnel plot (Supplementary
document—Supplementary Fig. 1, http://links.lww.com/SLA/B601)
for the primary outcome of infectious complications, and this was
found to show a minor degree of asymmetry, suggesting low risk of
publication bias. The risk of bias for the studies included is summa-
rized in Fig. 4.
DISCUSSION
What our Study Found?
The present meta-analysis has shown that the risk of develop-
ing infectious complications after surgery for gastrointestinal cancer
was reduced significantly by 48% in patients receiving preoperative
IMN. The intervention group also had a significant reduction in LOS
by 1.5 days, which may be related to the reduction in infectious
complications. However, the preoperative administration of IMN did
not impact noninfectious complications or mortality.
The studies included were from a wide spread of the world-
wide population and encompassed patients undergoing surgery for
different types of gastrointestinal cancer, each with their own inher-
ent risk of complications and morbidity. However, by encompassing
all of gastrointestinal cancer surgery, the results are more likely to be
generalizable. Although the IMN product used in all the studies was
Impact produced by Novartis/Nestle´ (Tokyo, Spain, Switzerland), the
volume of the product given and duration of treatment differed
ranging from a minimum of 3 days to a maximum of 8 days. These,
in part, may account for some of the variability seen in the range
of outcomes.
We assessed heterogeneity and found this to be low in the
primary outcome of infectious complications, and also the secondary
outcomes of noninfectious complications and mortality. The funnel
252 | www.annalsofsurgery.complot assessing publication bias also found a low risk of
publication bias.
What is Available in the Literature
Over the past 2 decades, several trials, as identified in this
systematic review, have been undertaken to investigate potential
benefits of IMN regarding postoperative outcome. Systematic
reviews have subsequently been carried out, with many of these
reporting improvement in postoperative outcomes, especially infec-
tious complications.10,14,15 IMN was found to reduce the rates of
postoperative infection and shorten LOS in another analysis.46
Studies that evaluated IMN and included a cost-effectiveness analy-
sis also suggested that perioperative IMN in upper gastrointestinal
surgery resulted in a decrease in complication rates, and also a
substantial decrease in treatment costs.47,48 The meta-analysis by
Marimathu et al15 concluded that IMN reduced postoperative com-
plications and decreased LOS. However, in their conclusion, they
reported that further work was required to evaluate IMN adminis-
tered preoperatively separate from perioperative and postoperative
treatment strategies. Hegazi et al16 undertook such a preoperative
assessment of IMN in patients undergoing gastrointestinal surgery.
They showed, in their subgroup analysis, that compared with patients
receiving nonsupplemented diets, there was a benefit of IMN in
reducing infectious complications and LOS. However, in those
studies where controls were given an isocaloric isonitrogenous
supplement, there was no additional benefit of IMN.16 The present
meta-analysis, using more contemporary data, has shown the benefit
of preoperative IMN in reducing infectious complications in controls
with and without isocaloric isonitrogenous supplementation for the
primary outcome of infectious complications. LOS was reduced
significantly when patients receiving IMN were compared with those
receiving a nonsupplemented diet, but not when compared with those
receiving isocaloric isonitrogenous supplements—the latter again in
line with the results from Hegazi et al.16 Nevertheless, taking into
account a higher heterogeneity (I2 ¼ 63%) in this subgroup and the
clear benefits regarding infectious complications, our results provide
arguments for the use of IMN in clinical practice.
The timing of IMN is of importance if it is to be effective in
offsetting the impact of postoperative inflammation and immuno-
suppression. For this effect to be realized, therapeutic levels of the
nutrients must be reached in plasma and tissues preoperatively.13 To
date, the evidence derived from animal studies suggests that 72 hours
were required for the effects of the enteral administered IMN to be
evidenced on macrophage phospholipid profile.11 In a study of
postoperative IMN administered to patients undergoing upper gas-
trointestinal resections, a total of 5 days was needed for the full dose
of IMN to be delivered.13 Sorensen et al49 reported a significant
uptake of v-3 fatty acids within 5 to 7 days of commencing oral
supplementation in patients undergoing surgery for colorectal can-
cer.49 In the present meta-analysis, significant differences in infec-
tious complications were seen mainly in studies in which IMN was
given for 5 to 7 days preoperatively, and the only study that gave it for
3 days30 did not show any difference. It would, therefore, follow that
a minimum of 5 to 7 days would be optimal for the intended benefits
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
FIGURE 2. Forest plots showing the pooled odds ratio (Mantel-Haenszel random-effects model) for (A) infectious complications
and (B) noninfectious complications. Subgroup analyses are based on controls receiving either ‘‘isocaloric isonitrogeneous
supplements’’ or ‘‘no supplements’’.
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FIGURE 3. Forest plots showing (A) the pooled weighted mean difference (inverse variance, random-effects model) for length of
stay and (B) the pooled odds ratio (Mantel-Haenszel random-effects model) for mortality. Subgroup analyses are based on controls
receiving either ‘‘isocaloric isonitrogeneous supplements’’ or ‘‘no supplements.’’
Adiamah et al Annals of Surgery  Volume 270, Number 2, August 2019of IMN on outcomes. Incidentally, treatment with IMN for more than
2 weeks did not show a further advantage, supposedly due to a
reduction in compliance.50
Giger-Pabst et al30 investigated ‘‘well-nourished’’ patients
undergoing surgery for all types of abdominal cancer in the only
254 | www.annalsofsurgery.comstudy in which IMN was administered for up to 3 days preoperatively
and demonstrated no benefit over isocaloric isonitrogenous control
diet. It is possible that the impact of IMN is potentially less in patients
who are well-nourished. More importantly, it is likely that treatment
duration of 3 days or less was insufficient for the effects of IMN to be
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
FIGURE 4. Risk of bias of the included studies using the
Cochrane Risk of Bias domains.
Annals of Surgery  Volume 270, Number 2, August 2019 Preoperative Immune Modulating Nutrition and Surgical Outcomeevident. That study30 is in direct contrast to the study by Braga et al,25
where all the study participants were malnourished and were treated
for a minimum of 5 days, with a demonstrable reduction in both
postoperative complications and LOS. Certain gastrointestinal can-
cers, especially upper gastrointestinal cancers, place patients at an
increased risk of severe malnutrition2 and the compound effect of
surgery causing dysregulation of immune response. IMN, therefore,
could be a feasible and beneficial treatment strategy in such patients.
The European Society for Clinical Nutrition and Metabolism
 2019 The Author(s). Published by Wolters Kluwer Health, Inc.(ESPEN) Clinical Guidelines, which were published in 2017, rec-
ommend IMN in malnourished patients undergoing major cancer
surgery.1,2 However, they accepted there was, at the time, no evi-
dence of benefit over standard oral nutritional supplements in the
preoperative period exclusively.1 This meta-analysis provides new
evidence supporting the use of preoperative IMN in patients under-
going surgery for gastrointestinal cancer. A recent study51 using
perioperative IMN in patients undergoing surgery for gastrointestinal
cancer and managed with an enhanced recovery after surgery proto-
col was able to demonstrate the benefit of IMN in reducing infectious
complications in that setting.
Strengths and Limitations of Our Study
Evaluating a nutrition-based intervention is always limited by
potential confounders such as compliance and potential for the
controls to be taking in foods with similar ingredients as is found
in IMN (arginine, fish oil, antioxidants). Even where reported, the
constituents of the isocaloric isonitrogeneous supplements were not
always obvious and may have contained low doses of similar
constituents as in IMN. Some smaller studies investigating IMN
in all gastrointestinal surgery failed to report if they had equal
number of patients undergoing similar procedures in each arm. Some
cancer surgery is associated with much longer in-patient stay than
others. Hence, in such smaller studies the impact of these variations
on LOS may be more pronounced. In addition, no studies had a
placebo-controlled arm, and comparisons of IMN were made with
isocaloric isonitrogenous supplements or no supplements. Almost all
studies provided between 750 and 1000 mL/d of IMN, with the
exception of the study by Moriya34 (who had a subset of patients
receiving what they classed as low dose IMN—250 mL/d). Compli-
ance and total amounts of IMN that each patient consumed were not
reported adequately to allow calculations of a dose response. It
would, therefore, seem reasonable to suggest a dose of 750 to
1000 mL/d of IMN.
That notwithstanding, this meta-analysis has assessed IMN
robustly, focusing on preoperative use solely in surgery for gastroin-
testinal cancer. The results are applicable and generalizable to this
population most at risk of malnutrition and its sequalae. There is an
expectation of a degree of methodological heterogeneity, given the
choice of nutritional supplementation, dosage, route of administra-
tion, population, and the varied cancer types and stage of disease
evaluated—this was accounted for by undertaking a random-effects
analysis. Finding low I2 values (which is a measure of the quantity of
heterogeneity) even when all of this variability is accounted for,
confirms the importance of our findings.
CONCLUSIONS
This meta-analysis provides contemporary evidence that pre-
operative administration of IMN for a minimum of 5 days, either
orally or enterally, leads to an appreciable and significant reduction
in postoperative infectious complications and a tendency for a
shortened LOS. Given the low side effect profile and the limited
cost, the results provide arguments to encourage IMN for patients
undergoing surgery for gastrointestinal cancer.
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